Skip to main content
ANTX
NASDAQ Life Sciences

AN2 Therapeutics Reports Narrower Q1 Loss, $85M Cash, and Extends Runway to 2029 with Multiple Pipeline Advancements

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$4.782
Mkt Cap
$169.899M
52W Low
$1
52W High
$6.91
52W Position info
378% above low
Off High info
31% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

ANTX has more than doubled off its 52-week low of $1 on light trading volume (0.2× avg).

Summary

AN2 Therapeutics reported a narrower net loss for Q1 2026, ending the quarter with $85.3 million in cash and investments, extending its operational runway into 2029. The company also provided positive updates on the advancement of several clinical and preclinical programs.


Key Events · Earnings and Guidance · ANTX

  • Q1 Financial Results

    Reported a net loss of $10.0 million for Q1 2026, a reduction from $10.6 million in Q1 2025.

  • Strong Cash Position & Runway

    Ended Q1 2026 with $85.3 million in cash, cash equivalents, and investments, projecting a cash runway into 2029.

  • Pipeline Advancement - Polycythemia Vera

    Oral epetraborole is advancing into a Phase 2 trial for polycythemia vera, with initiation planned for Q3 2026 and data readouts expected from Q4 2026.

  • Pipeline Advancement - M. abscessus

    Commenced a Phase 2 investigator-initiated trial of epetraborole for M. abscessus lung disease, with topline results anticipated in late 2027.


Analysis · ANTX · Life Sciences

This filing is highly important for AN2 Therapeutics as it provides a strong financial update, confirming a narrower net loss and a robust cash position of $85.3 million. Crucially, this cash is projected to fund operations into 2029, significantly de-risking the company's financial outlook following recent dilutive financings. The report also details the advancement of multiple key pipeline programs, including oral epetraborole into Phase 2 for polycythemia vera and M. abscessus lung disease, and AN2-502998 for Chagas disease, alongside a new oncology candidate. This combination of financial stability and clinical progress provides a clear positive signal for investors.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANTX was trading at $4.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $169.9M. The 52-week trading range was $1.00 to $6.91. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANTX - Latest Insights

ANTX
Nov 09, 2026, 7:33 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.00
Real-time Price: $5.08 info
Change: +$1.08 (+27%) info
Market Cap: $192.754M info
ANTX
Nov 02, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $4.54
Real-time Price: $5.08 info
Change: +$0.540 (+12%) info
Market Cap: $192.754M info
ANTX
Aug 11, 2026, 4:09 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.87
Real-time Price: $5.08 info
Change: -$0.790 (-13%) info
Market Cap: $192.754M info
ANTX
Aug 11, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.87
Real-time Price: $5.08 info
Change: -$0.790 (-13%) info
Market Cap: $192.754M info
ANTX
Aug 11, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.87
Real-time Price: $5.08 info
Change: -$0.790 (-13%) info
Market Cap: $192.754M info